Bright Minds Biosciences Inc. - common stock (DRUG)
33.15
+0.76 (2.35%)
Bright Minds Biosciences Inc. is a biopharmaceutical company focused on developing innovative therapies to treat various neuropsychiatric disorders
By leveraging advanced science and extensive research, the company aims to create new treatment options that address the underlying mechanisms of these conditions, ultimately improving the quality of life for patients. Their pipeline includes compounds that target unmet medical needs while prioritizing safety and efficacy. Through a combination of clinical trials and cutting-edge technology, Bright Minds seeks to advance the field of mental health treatment and contribute to the growing landscape of psychedelic-based medicine.
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQDRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).
Bright Minds Biosciences Inc (NASDAQDRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly Neuroscience.
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQDRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) NASDAQ: AIFFNASDAQAIFF)
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.
Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials.
The biotech world is buzzing as Bright Minds Biosciences (NASDAQDRUG) exploded yesterday with a +1500% surge, rocketing from $2.47 to $38.35 during regular trading, and hitting $50 in after-hours trading—marking a total rise of 1800% in a single day. With its market cap soaring from $4 million to $172 million, this dramatic short squeeze has caught the attention of investors everywhere. Bright Minds, a cutting-edge biotechnology company, is pioneering treatments for neurological and psychiatric disorders, including epilepsy and depression , with its innovative pipeline of selective serotonergic agonists aimed at transforming patient care. DRUG was featured in our pre-market spotlight on 10/15/2024 at just $2.47 per share see more.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQDRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQDRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences:
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ / CSE: DRUG) announces the Key Opinion Leader (KOL) event with leading experts in epilepsy research and treatment. The event will include Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will provide critical insights into the evolving landscape of drug-resistant seizures and the unmet needs in epilepsy care. These thought leaders will explore the scientific innovations driving the Phase 2 BREAKTHROUGH clinical trial design announced last week and highlight the potential for novel treatments.
Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.
